The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of tough-to-treat solid tumors.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...

Analysts questioned whether the complete response letter Replimune received was evidence of changing approval standards at ...

George Tidmarsh, a Stanford University physician who founded Horizon Pharma and later ran La Jolla Pharma, was named head of ...

Experts on the panel shared many of the same views around SSRIs, arguing that the risks of the drugs during pregnancy are greater than currently accepted.